Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kedrion IVIg 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)
NCT07059000Phase 3Recruiting
- Sponsor
- Kedrion Biopharma
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Countries
- 8
01
Overview
A Phase 3 trial of immune globulin intravenous (human) in immune thrombocytopenia (ITP), sponsored by Kedrion Biopharma. Started Aug 2025; status: recruiting.
02
Drugs
immune globulin intravenous (human)
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07059000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059000.